{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:03:21Z","timestamp":1790888601106,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031288","name":"F2G","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Treeline Biosciences"},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012317","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019123","name":"AiCuris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019123","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002424","name":"Fujifilm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Melinta"},{"DOI":"10.13039\/501100019123","name":"Aicuris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019123","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Botica Research Scholar Fund"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007299","name":"Harvard Clinical and Translational Science Center","doi-asserted-by":"publisher","award":["#1UL1TR002541-01"],"award-info":[{"award-number":["#1UL1TR002541-01"]}],"id":[{"id":"10.13039\/100007299","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Weitzman Family Scholar in Infectious Diseases"},{"DOI":"10.13039\/100005292","name":"Brigham and Women's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Invasive fusariosis (IF) is a rare but aggressive infection seen in immunocompromised patients that often exhibits elevated minimum inhibitory concentrations (MICs) to antifungal drugs, making the optimal therapeutic remains unknown. We identified all cases of IF between January 2015 and April 2024 and collected patient characteristics, including clinical presentation, therapy, and 12-week outcomes, as well as organism species identification and susceptibility testing. Twenty-one patients were diagnosed with either proven (n = 14) or probable (n = 7) IF. The mean age was 60 years and 71% were male. Hosts had hematologic disorders in 71% of which 80% had acute leukemia. Seventy-three percent were neutropenic at the time of IF diagnosis and 40% had received allogeneic stem cell transplantation. Infections were localized in 57% and disseminated in 43%. Skin was the most common site of involvement (67%), followed by pulmonary (42%) and sinus (21%). The most common species was Fusarium solani complex (38%). Susceptibility testing was performed on 81% of isolates. MICs were \u22654\u2005\u00b5g\/mL for mold-active triazoles in 94% and \u22651\u2005\u00b5g\/mL for terbinafine in 65%. The most common definitive regimens were a triazole plus terbinafine (62%) and triazole monotherapy (19%). Surgical debridement was performed in 52%. Seventy-six percent of patients survived to 12 weeks. Fifty-seven percent achieved complete responses, 29% partial responses, and 14% failed to respond to therapy at 12 weeks. Mortality in patients with IF is high. Despite elevated MICs, clinical responses to triazole antifungals with or without the addition of terbinafine are observed.<\/jats:p>","DOI":"10.1093\/ofid\/ofag248","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:43:21Z","timestamp":1778067801000},"source":"Crossref","is-referenced-by-count":1,"title":["Invasive Fusariosis: A Retrospective Case Series Evaluating In Vitro Minimum Inhibitory Concentrations and Clinical Response"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1811-6565","authenticated-orcid":false,"given":"Victor","family":"Kovac","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-7443","authenticated-orcid":false,"given":"Sarah P","family":"Hammond","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Medical Oncology, Massachusetts General Hospital Cancer Center , Massachusetts, Boston ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6596-0518","authenticated-orcid":false,"given":"Nicolas C","family":"Issa","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6616-920X","authenticated-orcid":false,"given":"Alexis","family":"Liakos","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-5647","authenticated-orcid":false,"given":"Jessica S","family":"Little","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C","family":"Sherman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R","family":"Baden","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E","family":"Woolley","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts ,","place":["USA"]},{"name":"Dana-Farber Cancer Institute Department of Medical Oncology, , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2026052306011353300_ofag248-B1","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1086\/324501","article-title":"Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections","volume":"33","author":"Anaissie","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2026052306011353300_ofag248-B2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/CMR.7.4.479","article-title":"Taxonomy, biology, and clinical aspects of fusarium species","volume":"7","author":"Nelson","year":"1994","journal-title":"Clin Microbiol Rev"},{"key":"2026052306011353300_ofag248-B3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00014-07","article-title":"Fusarium infections in immunocompromised patients","volume":"20","author":"Nucci","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2026052306011353300_ofag248-B4","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1086\/502102","article-title":"Epidemiology, molecular mycology, and environmental sources of fusarium infection in patients with cancer","volume":"23","author":"Raad","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026052306011353300_ofag248-B5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11046-024-00874-x","article-title":"Fusarium keratitis: a systematic review (1969 to 2023)","volume":"189","author":"Cintra","year":"2024","journal-title":"Mycopathologia"},{"key":"2026052306011353300_ofag248-B6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00452895","article-title":"Disseminated cutaneous and peritoneal hyalohyphomycosis caused by fusarium species: three cases and review of the literature","volume":"101","author":"Rippon","year":"1988","journal-title":"Mycopathologia"},{"key":"2026052306011353300_ofag248-B7","doi-asserted-by":"crossref","first-page":"ofv099","DOI":"10.1093\/ofid\/ofv099","article-title":"Invasive fusariosis in the voriconazole era: single-center 13-year experience","volume":"2","author":"Stempel","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2026052306011353300_ofag248-B8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QCO.0000000000001009","article-title":"Fusarium species central nervous system infection","volume":"37","author":"Strong","year":"2024","journal-title":"Curr Opin Infect Dis"},{"key":"2026052306011353300_ofag248-B9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/1469-0691.12126","article-title":"Mycotic keratitis: epidemiology, diagnosis and management","volume":"19","author":"Thomas","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2026052306011353300_ofag248-B10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/jof8040360","article-title":"Onychomycosis caused by fusarium Species","volume":"8","author":"Uemura","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2026052306011353300_ofag248-B11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V90.3.999","article-title":"Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years\u2019 experience at a cancer center and implications for management","volume":"90","author":"Boutati","year":"1997","journal-title":"Blood"},{"key":"2026052306011353300_ofag248-B12","doi-asserted-by":"crossref","first-page":"1105.e1","DOI":"10.1016\/j.cmi.2018.05.006","article-title":"Invasive mould disease in haematologic patients: comparison between fusariosis and aspergillosis","volume":"24","author":"Nucci","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026052306011353300_ofag248-B13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/1469-0691.12002","article-title":"Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil","volume":"19","author":"Nucci","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2026052306011353300_ofag248-B14","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"2026052306011353300_ofag248-B15","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1128\/AAC.00286-10","article-title":"International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole","volume":"54","author":"Lortholary","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052306011353300_ofag248-B16","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/jac\/dkaa516","article-title":"Do high MICs predict the outcome in invasive fusariosis?","volume":"76","author":"Nucci","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026052306011353300_ofag248-B17","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/AAC.02456-15","article-title":"International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for fusarium Species identified by molecular methods for the CLSI broth microdilution method","volume":"60","author":"Espinel-Ingroff","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052306011353300_ofag248-B18","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mould infections: an initiative of the European confederation of medical mycology in cooperation with the international society for human and animal mycology and the American society for microbiology","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026052306011353300_ofag248-B19","volume-title":"EUCAST Method for the determination of broth dilution Minimum inhibitory concentrations of antifungal agents for conidia forming moulds version 9.3","author":"Arendrup","year":"2015"},{"key":"2026052306011353300_ofag248-B20","volume-title":"M38-A2: reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard","author":"Clinical and Laboratory Standards Institute","year":"2008","edition":"2nd ed."},{"key":"2026052306011353300_ofag248-B21","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s10096-014-2111-1","article-title":"European confederation of medical mycology (ECMM) epidemiological survey on invasive infections due to fusarium species in Europe","volume":"33","author":"Tortorano","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026052306011353300_ofag248-B22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1469-0691.12465","article-title":"ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: fusarium spp., scedosporium spp. and others","volume":"20","author":"Tortorano","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2026052306011353300_ofag248-B23","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026052306011353300_ofag248-B24","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and European organization for research and treatment of cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026052306011353300_ofag248-B25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/cid\/ciad768","article-title":"Good outcomes in salvage therapy of fusariosis in patients with leukemia: is it the host or the drug?","volume":"79","author":"Matsuo","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026052306011353300_ofag248-B26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/jac\/dkad377","article-title":"Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes","volume":"79","author":"Matsuo","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026052306011353300_ofag248-B27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/cid\/ciae594","article-title":"Epidemiology and prognostic factors associated with mold-positive blood cultures: 10-year data from a French prospective surveillance program (2012-2022)","volume":"80","author":"Tala-Ighil","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026052306011353300_ofag248-B28","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1086\/429921","article-title":"Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay","volume":"40","author":"Marr","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2026052306011353300_ofag248-B29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/1469-0691.12409","article-title":"Improvement in the outcome of invasive fusariosis in the last decade","volume":"20","author":"Nucci","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2026052306011353300_ofag248-B30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1128\/jcm.24.4.507-511.1986","article-title":"Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts","volume":"24","author":"Doern","year":"1986","journal-title":"J Clin Microbiol"},{"key":"2026052306011353300_ofag248-B31","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1128\/AAC.46.10.3298-3300.2002","article-title":"In vitro activities of investigational triazoles against fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results","volume":"46","author":"Paphitou","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052306011353300_ofag248-B32","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1128\/AAC.41.4.808","article-title":"Effects of incubation temperature, inoculum size, and time of Reading on broth microdilution susceptibility test results for amphotericin B fgainst fusarium","volume":"41","author":"Pujol","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052306011353300_ofag248-B33","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/AAC.01445-09","article-title":"Efficacy of posaconazole as treatment and prophylaxis against fusarium solani","volume":"54","author":"Wiederhold","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052306011353300_ofag248-B34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijantimicag.2007.09.005","article-title":"In vitro interactions of antifungal agents against clinical isolates of fusarium spp","volume":"31","author":"C\u00f3rdoba","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2026052306011353300_ofag248-B35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2003.09.003","article-title":"In vitro interactions of licensed and novel antifungal drugs against fusarium spp","volume":"48","author":"Ortoneda","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026052306011353300_ofag248-B36","doi-asserted-by":"crossref","first-page":"ofae068","DOI":"10.1093\/ofid\/ofae068","article-title":"Adjunct terbinafine in patients with leukemia and invasive fusariosis with skin lesions: discordance between responses of skin lesions and systemic outcomes","volume":"11","author":"Matsuo","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026052306011353300_ofag248-B37","doi-asserted-by":"crossref","first-page":"e01244-19","DOI":"10.1128\/AAC.01244-19","article-title":"Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients","volume":"63","author":"Lamoth","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026052306011353300_ofag248-B38","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.11510","article-title":"Outcome predictors of 84 patients with hematologic malignancies and fusarium infection","volume":"98","author":"Nucci","year":"2003","journal-title":"Cancer"},{"key":"2026052306011353300_ofag248-B39","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/infdis\/164.5.944","article-title":"Experimental fusarial hyalohyphomycosis in a murine model","volume":"164","author":"Legrand","year":"1991","journal-title":"J Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag248\/68248079\/ofag248.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/5\/ofag248\/68248079\/ofag248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/5\/ofag248\/68248079\/ofag248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:01:24Z","timestamp":1779530484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag248\/8672713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag248","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,28]]},"article-number":"ofag248"}}